Navigation Links
Stemedica Announces the Appointment of Dr. Lev Verkh as Chief Regulatory and Clinical Development Officer
Date:6/13/2010

Stemedica announced today the appointment of Lev Verkh, PhD as Chief Regulatory and Clinical Development Officer. Dr. Verkh will be responsible for managing all regulatory activities and clinical trials on behalf of the company.

(PRWEB) June 11, 2010 -- Stemedica Cell Technologies, Inc., a leader in adult stem cell research and manufacturing, announced today the appointment of Lev Verkh, PhD as Chief Regulatory and Clinical Development Officer. Dr. Verkh will be responsible for managing all regulatory activities and clinical trials on behalf of the company. "Dr. Verkh brings over twenty years of international regulatory and clinical trial experience to Stemedica," said Dr. Nikolai Tankovich, Stemedica's President & Chief Medical Officer. "We are confident that his contribution to our mission to bring innovative products to patients, following FDA guidelines, will be significant."

Dr. Verkh's clinical and regulatory experience includes working for Pfizer, Baxter Bio Sciences, the Alliance Pharmaceutical Corporation and the Alpha Therapeutic Corporation. He has directed national and multi-national Phase I, II, III and IV clinical trials in such areas as cardiology, oncology, peripheral artery disease, hematology, blood disorders and imaging methods. He is author or co-author of over 40 peer-reviewed publications. Through his efforts and the efforts of his teams, he has received FDA approval for several products that are currently on the market. "I am honored to be joining Stemedica's management team," said Dr. Verkh, "and am excited to work with the company's leading-edge stem cell technology."

In addition to directing Stemedica's clinical trials within the United States, Dr.
'/>"/>

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Page: 1 2

Related biology technology :

1. Stemedica Completes Meeting with the FDA
2. United States Patent and Trademark Office Publishes Stemedica's Patent Application for the Treatment of Diabetic Retinopathy
3. The Jordanian Stem Cell Company Acquires Stem Cell Technology From Stemedica International S.A. - First Clinical Trail Anticipated To Begin Early 2010
4. Stemedica Achieves Major Milestone - Company Receives License to Manufacture Clinical Grade Stem Cells
5. Stemedica Selected By World Stem Cell Summit To Present Scientific Discoveries
6. Stemedica Requests Pre-IND Meeting With FDA
7. Stemedica Signs Scientific Advisory Board Agreement with Leading Pediatric Burn & Wound Care Researcher
8. Renowned Stem Cell Researcher Files Study Results With Stemedica
9. CIRM Completes Briefing Visit to Stemedica Cell Technologies
10. Stemedica Announces the Appointment of Dr. Michael Bayer as Director, Medical Services
11. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Stemedica Announces the Appointment of Dr. Lev Verkh as Chief Regulatory and Clinical Development Officer 
(Date:11/24/2014)... Nov. 24, 2014  Last week, Representatives ... (D-NC) took a bold bipartisan step on ... the OPEN Act. Original co-sponsors of the legislation ... Act will incentivize drug makers and innovators to ... and pediatric cancers, which opens the door to ...
(Date:11/24/2014)... One of the most extensive, widely cited digital ... now available to high school and junior college students and ... international society for optics and photonics , announced today that ... Library available to high schools for free and two-year ... to all areas of life in today’s world,” said SPIE ...
(Date:11/24/2014)... , Nov. 24, 2014  Spherix Incorporated ... company committed to the fostering and monetization of ... v. VTech Telecommunications Ltd.,  Case No. 3:13-cv-03494-M and  ... No. 3:13-cv-03496-M, both in the United States District ... Texas . On November ...
(Date:11/22/2014)... VA (PRWEB) November 21, 2014 During ... who understood the need to surround himself with great ... CEO and entrepreneur, his friends often marveled at his ... he lived his life and -- even with his ... for the Alzheimer’s disease that would ultimately take his ...
Breaking Biology Technology:OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2SPIE Digital Library Now Available to High Schools, Two-Year Colleges at No or Low Cost 2Markman Hearing Held as Scheduled in VTech and Uniden Cases 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 3
... , , , ... ADL), a US-based pharmaceutical company with major assets in China, announced today ... of the Company as " Radient Pharmaceuticals Corporation" . ... will be "RPC" . The Company has filed an ...
... , SEATTLE, Sept. 18 Omeros Corporation ... 6.82 million shares of its common stock. Omeros is ... products focused on inflammation and disorders of the central nervous ... for the initial public offering is $10.00 to $12.00 per ...
... , , SAN MATEO, ... a biopharmaceutical company focused on developing and commercializing novel pain management ... is scheduled to present at the UBS Global Life Sciences Conference, ... City. , , Mr. DiTonno and Stephen ...
Cached Biology Technology:AMDL Inc. Announces Stockholder Approval of Name Change and Issuance of a New Trading Symbol on the NYSE Alternext US 2AMDL Inc. Announces Stockholder Approval of Name Change and Issuance of a New Trading Symbol on the NYSE Alternext US 3AMDL Inc. Announces Stockholder Approval of Name Change and Issuance of a New Trading Symbol on the NYSE Alternext US 4AMDL Inc. Announces Stockholder Approval of Name Change and Issuance of a New Trading Symbol on the NYSE Alternext US 5Omeros Commences Initial Public Offering of Common Stock 2Omeros Commences Initial Public Offering of Common Stock 3NeurogesX to Present at UBS Global Life Sciences Conference 2NeurogesX to Present at UBS Global Life Sciences Conference 3
(Date:11/18/2014)... , Nov. 17, 2014 The Parenteral Drug ... U.S. regulatory agencies will speak and at least seven more ... Conference at the Omni Shoreham Hotel in Washington ... once again to have significant support from the regulatory agencies ... Europe in our effort to help advance ...
(Date:11/12/2014)... Nov. 12, 2014 Crossmatch™, a leading provider ... U.are.U ® fingerprint readers have been deployed throughout ... Central Mexico . The bakery chain implemented ... payroll issues caused by employees clocking in for each ... fingerprint readers, Montparnasse relied on paper timecards and a ...
(Date:11/7/2014)... associate professor, biomedical engineering, in the Grove School ... York, have identified a molecule that could lead ... aggressive forms of breast cancer. , Triple negative ... owing to aggressive proliferation and metastasis and a ... team, discovered the overexpression of intercellular adhesion molecule-1 ...
Breaking Biology News(10 mins):FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... recorded during a record-setting expedition have yielded new insights ... in the cold, dark, and highly pressurized habitats of ... Natalya Gallo of Scripps Institution of Oceanography at ... DEEPSEA CHALLENGE expedition, a project led by James Cameron ...
... his doctoral student Nicole Bance are among an international group ... compounds capable of killing the influenza virus. , Working ... can be a killer, the scientists have advanced previous researchers, ... influenza replicates and spreads. , Their new compounds will ...
... 21, 2013) Cardiovascular disease specialists at Florida Hospital Pepin ... with the University of South Florida announced they have enrolled ... gene therapy for the treatment of heart failure after ischemic ... tissue by encouraging the body to deploy more stem cells ...
Cached Biology News:Vibrant mix of marine life found at extreme ocean depths, Scripps analysis reveals 2Vibrant mix of marine life found at extreme ocean depths, Scripps analysis reveals 3Influenza study: Meet virus' new enemy 2New therapy for heart failure may enhance body's stem cell response at cardiovascular injury site 2New therapy for heart failure may enhance body's stem cell response at cardiovascular injury site 3
Mouse monoclonal antibody to QPCT - glutaminyl-peptide cyclotransferase (glutaminyl cyclase)...
...
... is a new product number, ... product number. If showing no ... the old Sigma-Aldrich number (Z71,669-3) ... assistance. ID clarifier: barcoded Mfr ...
Rabbit polyclonal to YANK2 ( Abpromise for all tested applications). Antigen: A KLH conjugated synthetic peptide selected within aa 300~400 (C terminal region) of human YANK2. Entrez Gene ID:...
Biology Products: